A consolidated working classification of gastric cancer for histopathologists (Review)
- Authors:
- Simona Costache
- Maria Sajin
- Sarah Wedden
- Corrado D'Arrigo
-
Affiliations: University of Medicine and Pharmacy ‘Carol Davila’, 020021 Bucharest, Romania, Cancer Diagnostic Quality Assurance Services (CADQAS), Dorchester DT13BJ, UK, Poundbury Cancer Institute, Dorchester DT13BJ, UK - Published online on: July 19, 2023 https://doi.org/10.3892/br.2023.1640
- Article Number: 58
-
Copyright: © Costache et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Johnston FM and Beckman M: Updates on management of gastric cancer. Curr Oncol Rep. 21(67)2019.PubMed/NCBI View Article : Google Scholar | |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Rawla P and Barsouk A: Epidemiology of gastric cancer: Global trends, risk factors and prevention. Prz Gastroenterol. 14:26–38. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 8(CD004064)2017.PubMed/NCBI View Article : Google Scholar | |
|
Park SR, Chun JH, Kim YW, Lee JH, Choi IJ, Kim CG, Lee JS, Bae JM and Kim HK: Phase II study of low-dose Docetaxel/Fluorouracil/Cisplatin in metastatic gastric carcinoma. Am J Clin Oncol. 28:433–438. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Sun DS, Jeon EK, Won HS, Park JC, Shim BY, Park SY, Hong YS, Kim HK and Ko YH: Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer. Gastric Cancer. 18:644–652. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C and Sakata Y: Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 14:72–80. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van De Velde CJH, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Laurén P: The two histological main types of gastric carcinoma: Diffuse and So-called Intestinal-type carcinoma: An attempt at a Histo-clinical classification. Acta Pathol Microbiol Scand. 64:31–49. 1965.PubMed/NCBI View Article : Google Scholar | |
|
Carneiro F, Seixas M and Sobrinho-Simões M: New elements for an updated classification of the carcinomas of the stomach. Pathol Res Pract. 191:571–584. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, Zeng Q, Zeng L, Pan Y, Chen ZS, et al: Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 7(358)2022.PubMed/NCBI View Article : Google Scholar | |
|
Monster JL, Kemp LJS, Gloerich M and Van Der Post RS: Diffuse gastric cancer: Emerging mechanisms of tumor initiation and progression. Biochim Biophys Acta Rev Cancer. 1877(188719)2022.PubMed/NCBI View Article : Google Scholar | |
|
Organisation mondiale de la santé and Centre international de Recherche Sur le cancer: Digestive system tumours. 5th edition. International agency for research on cancer, Lyon, 2019. | |
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al: Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netws. 20:167–192. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Davidson B and Tropé CG: Ovarian cancer: Diagnostic, biological and prognostic aspects. Womens Health (Lond). 10:519–533. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R, Nitsche U, et al: Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 134:552–562. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J and Shi B: Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 5:2929–2943. 2015.PubMed/NCBI | |
|
Talhouk A and McAlpine JN: New classification of endometrial cancers: The development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 3(14)2016.PubMed/NCBI View Article : Google Scholar | |
|
West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA and Salgia R: A novel classification of lung cancer into molecular subtypes. PLoS One. 7(e31906)2012.PubMed/NCBI View Article : Google Scholar | |
|
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21:449–456. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Wong SS, Kim KM, Ting JC, Yu K, Fu J, Liu S, Cristescu R, Nebozhyn M, Gong L, Yue YG, et al: Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. Nat Commun. 5(5477)2014.PubMed/NCBI View Article : Google Scholar | |
|
Chia NY and Tan P: Molecular classification of gastric cancer. Ann Oncol. 27:763–769. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Alsina M, Arrazubi V, Diez M and Tabernero J: Current developments in gastric cancer: From molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 20:155–170. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, et al: A protein and mRNA expression-based classification of gastric cancer. Modern Pathol. 29:772–784. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Organisation mondiale de la santé and Centre international de Recherche Sur le cancer: Female genital tumours. 5th edition. International agency for research on cancer, Lyon, 2020. | |
|
Ramos MFKP, Pereira MA, Amorim LC, Mello ES, Faraj SF, Ribeiro U, Hoff PMG, Cecconello I and Castria TB: Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype? J Surg Oncol. 121:804–813. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ahn S, Lee SJ, Kim Y, Kim A, Shin N, Choi KU, Lee CH, Huh GY, Kim KM, Setia N, et al: High-throughput Protein and mRNA Expression-based classification of gastric cancers can identify clinically distinct subtypes, concordant with recent molecular classifications. Am J Surg Pathol. 41:106–115. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhao C, Feng Z, He H, Zang D, Du H, Huang H, Du Y, He J, Zhou Y and Nie Y: Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray. PLoS One. 15(e0238836)2020.PubMed/NCBI View Article : Google Scholar | |
|
Park S, Ahn S, Kim DG, Kim H, Kang SY and Kim KM: High frequency of juxtamembrane domain ERBB2 mutation in gastric cancer. Cancer Genomics Proteomics. 19:105–112. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, et al: Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell. 36:444–457.e7. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, MacArthur DG, et al: The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 581:434–443. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discovery. 2:401–404. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Gravalos C and Jimeno A: HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol. 19:1523–1529. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Wilding B, Scharn D, Böse D, Baum A, Santoro V, Chetta P, Schnitzer R, Botesteanu DA, Reiser C, Kornigg S, et al: Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling. Nat Cancer. 3:821–836. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhu Y, Zhu X, Wei X, Tang C and Zhang W: HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer. 1876(188549)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kahraman S and Yalcin S: Recent advances in systemic treatments for HER-2 positive advanced gastric cancer. Onco Targets Ther. 14:4149–4162. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Adua D, Di Fabio F, Rojas Llimpe FL, Pini S and Pinto C: Long-term survival in an advanced gastric cancer patient treated with cetuximab in association with FOLFIRI: A case report. J Gastrointest Oncol. 5:E13–E17. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, et al: Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer. 18:824–832. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 390:2461–2471. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al: Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 17:717–726. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, et al: CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol. 36:2836–2844. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Kim JW, Lee HS, Nam KH, Ahn S, Kim JW, Ahn SH, Park DJ, Kim HH and Lee KW: PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. Oncotarget. 8:90948–90958. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Te Paske IBAW, Garcia-Pelaez J, Sommer AK, Matalonga L, Starzynska T and Jakubowska A: Solve-RD-GENTURIS group. van der Post RS, Lubinski J, Oliveira C, et al: A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: Case report. Eur J Hum Genet. 29:1354–1358. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Polom K, Das K, Marrelli D, Roviello G, Pascale V, Voglino C, Rho H, Tan P and Roviello F: KRAS mutation in gastric cancer and prognostication associated with microsatellite instability status. Pathol Oncol Res. 25:333–340. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Salem M, El-Refai S, Sha W, Grothey A, Puccini A, George T, Hwang J, Kadakia K, Musselwhite L, Van Cutsem E, et al: O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies. Ann Oncol. 32(S218)2021. | |
|
Osterlund E, Ristimäki A, Kytölä S, Kuopio T, Heervä E, Muhonen T, Halonen P, Kallio R, Soveri LM, Sundström J, et al: KRAS-G12C mutation in one Real-life and three population-based Nordic cohorts of metastatic colorectal cancer. Front Oncol. 12(826073)2022.PubMed/NCBI View Article : Google Scholar | |
|
Chida K, Kotani D, Masuishi T, Kawakami T, Kawamoto Y, Kato K, Fushiki K, Sawada K, Kumanishi R, Shirasu H, et al: The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study. Oncologist. 26:845–853. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, et al: ALK inhibitors in patients with ALK Fusion-positive GI cancers: An international data set and a molecular case series. JCO Precis Oncol. 6(e2200015)2022.PubMed/NCBI View Article : Google Scholar | |
|
Chon HJ, Kim HR, Shin E, Kim C, Heo SJ, Lee C, Park JK, Noh SH, Chung HC and Rha SY: The Clinicopathologic features and prognostic impact of ALK positivity in patients with resected gastric cancer. Ann Surg Oncol. 22:3938–3945. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, et al: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA. 103:2316–2321. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, Shah M, Christensen JG, Rosen N, Solit DB, et al: HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 7:3499–3508. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H and Tahara E: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 189:227–232. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Seruca R, Suijkerbuijk RF, Gärtner F, Criado B, Veiga I, Olde-Weghuis D, David L, Castedo S and Sobrinho-Simões M: Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer. Cancer Genet Cytogenet. 82:140–145. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Tsujimoto H, Sugihara H, Hagiwara A and Hattori T: Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Archiv. 431:383–389. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Sakakura C, Mori T, Sakabe T, Ariyama Y, Shinomiya T, Date K, Hagiwara A, Yamaguchi T, Takahashi T, Nakamura Y, et al: Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosom Cancer. 24:299–305. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC and Shah MA: MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 20:1021–1027. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Xu B, Chen F, Zhang X, Wang Z, Che K, Wu N, Yu L, Fan X, Liu B and Wei J: Antigen-Specific T cell immunotherapy targeting Claudin18.2 in gastric cancer. Cancers. 14(2758)2022.PubMed/NCBI View Article : Google Scholar | |
|
Grizzi G, Venetis K, Denaro N, Bonomi M, Celotti A, Pagkali A, Hahne JC, Tomasello G, Petrelli F, Fusco N, et al: Anti-Claudin treatments in gastroesophageal adenocarcinoma: Mainstream and upcoming strategies. J Clin Med. 12(2973)2023.PubMed/NCBI View Article : Google Scholar | |
|
Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, Zhang M, Peng Z, Zhou J, Cao Y, et al: Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results. Nat Med. 28:1189–1198. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B, et al: FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 32:609–619. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Alexa M, Hasenburg A and Battista MJ: The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. Cancers. 13(1478)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wedden S, Miller K, Frayling IM, Thomas T, Chefani A, Miller K, Hamblin A, Taylor JC and D'Arrigo C: Colorectal cancer stratification in the routine clinical pathway: A district general hospital experience. Appl Immunohistochem Mol Morphol. 27:e54–e62. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Fremond S, Andani S, Barkey Wolf J, Dijkstra J, Melsbach S, Jobsen JJ, Brinkhuis M, Roothaan S, Jurgenliemk-Schulz I, Lutgens LCHW, et al: Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and Eosin-stained Whole-slide images: A combined analysis of the PORTEC randomised trials and clinical cohorts. Lancet Digital Health. 5:e71–e82. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Fell C, Mohammadi M, Morrison D, Arandjelović O, Syed S, Konanahalli P, Bell S, Bryson G, Harrison DJ and Harris-Birtill D: Detection of malignancy in whole slide images of endometrial cancer biopsies using artificial intelligence. PLoS One. 18(e0282577)2023.PubMed/NCBI View Article : Google Scholar |
